Immutep’s data for ASCO darling LAG3 raise survival questions

The LAG3 checkpoint target stole the show at this year’s ASCO conference, but the latest data from Immutep at SITC are raising questions about survival benefits of one of the most advanced LAG3 therapies in the pipeline. 

Those concerns shouldn’t read through to other LAG3 programs because Immutep Ltd. (ASX:IMM; NASDAQ:IMMP) is targeting a different function of the receptor than competitors, and they may be addressed by narrowing the patient population...